License and collaboration agreements - Additional Information (Details) - USD ($) $ in Thousands		3 Months Ended	12 Months Ended
	Jun. 11, 2021	Mar. 31, 2022	Dec. 31, 2020	Dec. 31, 2021	Mar. 31, 2021
Research And Development Arrangement Contract To Perform For Others [Line Items]
Upfront payment received		$ 625,000
License and collaboration revenue		152,522
Deferred Revenue		127,703		$ 280,225
Adimab L L C
Research And Development Arrangement Contract To Perform For Others [Line Items]
Maximum additional receivable based on achievement of research milestones		14,500	$ 1,000
Adimab L L C | License revenue
Research And Development Arrangement Contract To Perform For Others [Line Items]
License and collaboration revenue		3,400
Adimab L L C | Development Regulatory and Sales Milestone
Research And Development Arrangement Contract To Perform For Others [Line Items]
Maximum option fees receivable based on achievement of research milestones		$ 45,800
GSK
Research And Development Arrangement Contract To Perform For Others [Line Items]
Upfront payment received	$ 625,000
Milestone payments	$ 1,450,000
Costs related to global development plan		60.00%
Due to related parties		$ 100		3,000
Related party transaction, expenses from transactions with related party		900,000
Eligible royalty payments percentage	20.00%
Deferred Revenue		127,700		$ 280,200
Costs related to the cost-sharing provisions		5,200
Reimbursable by GSK		100
Capitalized contract cost					$ 6,800
GSK | License revenue
Research And Development Arrangement Contract To Perform For Others [Line Items]
License and collaboration revenue		$ 152,500